Regeneron Pharmaceuticals
REGN
452 hedge funds and large institutions have $22.3B invested in Regeneron Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 180 increasing their positions, 150 reducing their positions, and 48 closing their positions.
48% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 48
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
20% more repeat investments, than reductions
Existing positions increased: 180 | Existing positions reduced: 150
7% more capital invested
Capital invested by funds: $20.9B → $22.3B (+$1.4B)
3% more funds holding
Funds holding: 437 → 452 (+15)
20% less call options, than puts
Call options by funds: $382M | Put options by funds: $479M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$324M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$202M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$185M |
| 4 |
VAM
Visium Asset Management
New York
|
+$88.3M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
+$86.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$584M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$462M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$379M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$107M |
| 5 |
JP Morgan Chase
New York
|
-$84.4M |
REGN Hedge Fund Activity: Q1 2014 in Review
452 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2014, worth a combined $22.3B — up 6.7% from $20.9B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new REGN positions and 48 closed out — a net gain of 23 holders — while 180 added to existing stakes and 150 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $324M. The largest seller was T. Rowe Price Associates, cutting an estimated $584M.
- 452 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2014, up from 437 in Q4 2013.
- Funds reported $22.3B of Regeneron Pharmaceuticals stock for Q1 2014, up 6.7% quarter-over-quarter.
- 71 funds opened new Regeneron Pharmaceuticals positions in Q1 2014 and 48 closed out, a net change of +23 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2014 was Viking Global Investors, an estimated $324M added.
- The largest Regeneron Pharmaceuticals seller in Q1 2014 was T. Rowe Price Associates, an estimated $584M sold.
Based on aggregated 13F filings for Q1 2014.